184 related articles for article (PubMed ID: 33050567)
21. Fluorimetric determination of febuxostat in dosage forms and in real human plasma via Förster resonance energy transfer.
El-Gizawy SM; Atia NN; Hosny NM
Luminescence; 2018 Aug; 33(5):877-884. PubMed ID: 29687589
[TBL] [Abstract][Full Text] [Related]
22. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
[TBL] [Abstract][Full Text] [Related]
23. Rutamarin, an Active Constituent from
Suhaimi SA; Hong SL; Abdul Malek SN
Pharmacogn Mag; 2017 Jul; 13(Suppl 2):S179-S188. PubMed ID: 28808378
[TBL] [Abstract][Full Text] [Related]
24. Antiproliferative and apoptotic activities of 8-prenylnaringenin against human colon cancer cells.
Koosha S; Mohamed Z; Sinniah A; Ibrahim ZA; Seyedan A; Alshawsh MA
Life Sci; 2019 Sep; 232():116633. PubMed ID: 31278947
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Khosravan R; Grabowski BA; Wu JT; Joseph-Ridge N; Vernillet L
Clin Pharmacokinet; 2006; 45(8):821-41. PubMed ID: 16884320
[TBL] [Abstract][Full Text] [Related]
26. Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes.
Lytvyn Y; Har R; Locke A; Lai V; Fong D; Advani A; Perkins BA; Cherney DZI
Diabetes; 2017 Jul; 66(7):1939-1949. PubMed ID: 28408434
[TBL] [Abstract][Full Text] [Related]
27. Optimized Icariin Phytosomes Exhibit Enhanced Cytotoxicity and Apoptosis-Inducing Activities in Ovarian Cancer Cells.
Alhakamy NA; A Fahmy U; Badr-Eldin SM; Ahmed OAA; Asfour HZ; Aldawsari HM; Algandaby MM; Eid BG; Abdel-Naim AB; Awan ZA; K Alruwaili N; Mohamed AI
Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32290412
[TBL] [Abstract][Full Text] [Related]
28. Chitosan-based nano-in-microparticle carriers for enhanced oral delivery and anticancer activity of propolis.
Elbaz NM; Khalil IA; Abd-Rabou AA; El-Sherbiny IM
Int J Biol Macromol; 2016 Nov; 92():254-269. PubMed ID: 27397719
[TBL] [Abstract][Full Text] [Related]
29. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
[TBL] [Abstract][Full Text] [Related]
30. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
31. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
[TBL] [Abstract][Full Text] [Related]
32. Long-term adherence and persistence with febuxostat among male patients with gout in a routine clinical setting.
Lee S; So MW; Ahn E
Mod Rheumatol; 2019 Jul; 29(4):662-668. PubMed ID: 29856667
[No Abstract] [Full Text] [Related]
33. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
Bruce SP
Ann Pharmacother; 2006 Dec; 40(12):2187-94. PubMed ID: 17132810
[TBL] [Abstract][Full Text] [Related]
34. Curcumin Reverses 5-Fluorouracil Resistance by Promoting Human Colon Cancer HCT-8/5-FU Cell Apoptosis and Down-regulating Heat Shock Protein 27 and P-Glycoprotein.
He WT; Zhu YH; Zhang T; Abulimiti P; Zeng FY; Zhang LP; Luo LJ; Xie XM; Zhang HL
Chin J Integr Med; 2019 Jun; 25(6):416-424. PubMed ID: 30484020
[TBL] [Abstract][Full Text] [Related]
35. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
36. Optimized Apamin-Mediated Nano-Lipidic Carrier Potentially Enhances the Cytotoxicity of Ellagic Acid against Human Breast Cancer Cells.
Badr-Eldin SM; Aldawsari HM; Fahmy UA; Ahmed OAA; Alhakamy NA; Al-Hejaili OD; Alhassan AA; Ammari GA; Alhazmi SI; Alawadi RM; Bakhaidar R; Alamoudi AJ; Neamatallah T; Tima S
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012704
[TBL] [Abstract][Full Text] [Related]
37. The variable chemotherapeutic response of Malabaricone-A in leukemic and solid tumor cell lines depends on the degree of redox imbalance.
Manna A; De Sarkar S; De S; Bauri AK; Chattopadhyay S; Chatterjee M
Phytomedicine; 2015 Jul; 22(7-8):713-23. PubMed ID: 26141757
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Fleischmann R; Kerr B; Yeh LT; Suster M; Shen Z; Polvent E; Hingorani V; Quart B; Manhard K; Miner JN; Baumgartner S;
Rheumatology (Oxford); 2014 Dec; 53(12):2167-74. PubMed ID: 24509406
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
Gunawardhana L; Becker MA; Whelton A; Hunt B; Castillo M; Saag K
Arthritis Res Ther; 2018 May; 20(1):99. PubMed ID: 29848361
[TBL] [Abstract][Full Text] [Related]
40. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
